Stockscreener 앱 받기
54.68
2.44%
-1.37
시간 외 거래:
55.00
0.32
+0.59%
전일 마감가:
$56.05
열려 있는:
$56.32
하루 거래량:
2.62M
Relative Volume:
1.01
시가총액:
$10.58B
수익:
$3.29B
순이익/손실:
$268.74M
주가수익비율:
39.90
EPS:
1.3704
순현금흐름:
$759.12M
1주 성능:
-0.21%
1개월 성능:
-15.53%
6개월 성능:
+1.07%
1년 성능:
+3.27%
1일 변동 폭
$54.44
$56.53
1주일 범위
$53.93
$57.59
52주 변동 폭
$49.26
$70.98
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.68 | 10.58B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-15 | 재개 | UBS | Buy |
| 2026-10-12 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2026-08-19 | 개시 | BMO Capital Markets | Outperform |
| 2026-05-19 | 개시 | Citigroup | Buy |
| 2026-05-11 | 재개 | Goldman | Neutral |
| 2026-04-27 | 재개 | Morgan Stanley | Overweight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-20 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Raymond James upgrades BioMarin stock to strong buy on valuation - Investing.com
Why is BioMarin Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada
Raymond James upgrades BioMarin stock to strong buy on valuation By Investing.com - Investing.com South Africa
Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN) - The Globe and Mail
RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin to present data on achondroplasia treatment at ASBMR - Investing.com
New imaging data examine a growth drug's effect on a skull area linked to serious complications in children. - Stock Titan
BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention? - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
RBC Capital lowers BioMarin price target to $62 - scanx.trade
Citigroup raises BioMarin price target to $76 - scanx.trade
BioMarin names Cara Bauer as chief people officer - Investing.com
BioMarin Appoints Cara Bauer as Chief People Officer - PR Newswire
BioMarin presents five-year data on Pompe disease treatment - Investing.com
BioMarin presents five-year data on Pompe disease treatment By Investing.com - Investing.com Canada
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress - PR Newswire
BioMarin Pharmaceutical (NasdaqGS:BMRN) Stock Forecast & Analyst Predictions - Simply Wall Street
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada
Profluent and BioMarin Partner to Design Novel Enzyme Therapies Using AI - HLTH
After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. - Stock Titan
The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) - Yahoo Finance
BioMarin and Profluent partner on AI-designed enzyme therapies - Pharmaceutical Technology
Major North Bay biotech employer to cut 119 jobs in consolidation move - The Press Democrat
Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 - TradingView
BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 - TradingView
Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI - marketscreener.com
Profluent Partners With BioMarin to Design Novel Medicines Using AI - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts - au.finance.yahoo.com
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance UK
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance Singapore
BioMarin Pharmaceutical Inc. (BMRN) Latest Stock News & Headlines - Yahoo Finance
BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. (BMRN): Stock Analysis Reveals 43% Potential Upside - DirectorsTalk Interviews
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? - Yahoo Finance
Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative? - Yahoo Finance
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone - Yahoo Finance
BioMarin Stops Voxzogo Development for Noonan Syndrome - Yahoo Finance
BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units - Stock Titan
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board - TradingView
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com
BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView
BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com India
BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView
BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com Canada
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오마린 주식 (BMRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Davis George Eric | Officer |
Sep 02 '26 |
Proposed Sale |
66.28 |
17,557 |
1,163,756 |
0 |
| Friberg Gregory R | EVP, Chief R&D Officer |
May 07 '26 |
Sale |
53.85 |
3,281 |
176,682 |
51,818 |
| Friberg Gregory R | Officer |
May 07 '26 |
Proposed Sale |
53.85 |
3,281 |
176,682 |
0 |
| Guyer Charles Greg | EVP, Chief Technical Officer |
Mar 11 '26 |
Sale |
60.46 |
16,486 |
996,744 |
79,953 |
| Guyer Charles Greg | Officer |
Mar 11 '26 |
Proposed Sale |
60.46 |
16,486 |
996,749 |
0 |
| Friberg Gregory R | EVP, Chief R&D Officer |
Feb 26 '26 |
Sale |
60.38 |
6,326 |
381,937 |
37,578 |
| Davis George Eric | EVP, Chief Legal Officer |
Feb 26 '26 |
Sale |
61.36 |
26,061 |
1,599,103 |
72,453 |
| Friberg Gregory R | Officer |
Feb 26 '26 |
Proposed Sale |
60.38 |
6,326 |
381,937 |
0 |
| Davis George Eric | Officer |
Feb 26 '26 |
Proposed Sale |
61.36 |
26,061 |
1,599,103 |
0 |
2.19%
0.07%
자본화:
|
볼륨(24시간):